| abstract |
The present invention relates to the use of at least one compound comprising the amino acid sequence n (X 1 ) n X 2 X 3 PVX 4 X 5 X6(X 7 ) m (Formula 1), nwherein nX 1 is any amino acid residue, nX 2 is an amino acid residue selected from the group consisting of aspartic acid (D) and glutamic acid (E), nX 3 is any amino acid residue, nX 4 is any amino acid residue, nX 5 is an amino acid residue selected from the group consisting of proline (P) and alanine (A), nX 6 is an amino acid residue selected from the group consisting of aspartic acid (D) and glutamic acid (E), nX 7 is any amino acid residue, nn and m, independently, are 0 or an integer of more than 0, nand wherein the amino acid sequence according to Formula I is not identical with, or does not comprise the 8-mer polypeptide fragment of alpha-synuclein having the amino acid sequence DMPVDPDN, nsaid compound having a binding capacity to an antibody which is specific for an epitope of alpha-synuclein comprising the amino acid sequence DMPVDPDN nfor producing a medicament for preventing and/or treating synucleinopathies. |